By indication / Breast cancer
Breast cancer
21 imaging agents and 23 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [68Ga]Ga-RM2 paired with [111In]In-RM2 | Ga-68 | Clinical research | 7 |
| [18F]FES | F-18 | Approved | 5 |
| [18F]FB-HER2 | F-18 | — | 2 |
| [68Ga]Ga-ABY-025 | Ga-68 | — | 2 |
| [89Zr]DFO-F8 | Zr-89 | Reported once | 2 |
| [18F]GE-226 | F-18 | Research | 1 |
| [18F]AlF-NOTA-FAPI-04 | F-18 | — | 1 |
| [18F]FB-4AH29 | F-18 | Preclinical | 1 |
| [18F]mBPET-1 | F-18 | — | 1 |
| [89Zr]Zr-DFO-girentuximab | Zr-89 | Clinical research | 1 |
| [68Ga]DOTA-KiSS-34 paired with [177Lu]Lu-DOTA-KiSS-34 | Ga-68 | Reported once | 1 |
| [89Zr]DFO-11E10C11 | Zr-89 | Preclinical | 1 |
| [89Zr]DFO-NY003/ | Zr-89 | Preclinical | 1 |
| [124I]PN67 paired with [131I]PN67 | I-124 | Reported once | 1 |
| [99mTc]Tc(CO)3-ADAPT6 | Tc-99m | Preclinical | 1 |
| [18F]AH113804 | F-18 | Research | |
| [18F]FBNA | F-18 | Preclinical | |
| 2-[18F]fluoro-myo-inositol | F-18 | Preclinical | |
| [18F]FluorThanatrace | F-18 | — | |
| [18F]L-Glutamic | F-18 | Clinical research | |
| [89Zr]trastuzumab-PEG6-DM1 | Zr-89 | Reported once |
Therapy
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [225Ac]Ac-DOTA-trastuzumab | Ac-225 | Preclinical | 4 |
| [212Pb]Pb-212-TCMC-trastuzumab | Pb-212 | Clinical research | 2 |
| [225Ac]Ac-225-PRIT | Ac-225 | Preclinical | 2 |
| [188Re]Re-188-DTPA-deoxyglucose | Re-188 | — | 2 |
| [111In]pb12 | In-111 | Preclinical | 2 |
| [177Lu]Lu-FAP-2286 paired with [68Ga]Ga-FAP-2286 | Lu-177 | Clinical research | 1 |
| [177Lu]Lu-DOTA-trastuzumab | Lu-177 | Clinical research | 1 |
| [225Ac]Ac-90-NM600 | Ac-225 | Preclinical | 1 |
| [225Ac]Ac-hu11B6 | Ac-225 | — | 1 |
| [225Ac]Ac-DOTA-2Rs15d | Ac-225 | Preclinical | 1 |
| [131I]I-131-PD-L1 | I-131 | — | 1 |
| [131I]I-Tyr-d-peptide-PEG11-Tz | I-131 | Reported once | 1 |
| [131I]I-WS03 | I-131 | Preclinical | 1 |
| [177Lu]Lu-DOTA-KiSS-34 paired with [68Ga]DOTA-KiSS-34 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-11E10C11 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-CHX-A''-DTPA-F8 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-DOTA-iPD-L1 | Lu-177 | Preclinical | 1 |
| [225Ac]Ac-Macropa-N4MU01 | Ac-225 | Reported once | 1 |
| [177Lu]Lu-DTPA-NY003 | Lu-177 | Preclinical | 1 |
| [123I]PARPi-01 | I-123 | Preclinical | 1 |
| [125I]PARPi-01 | I-125 | Preclinical | 1 |
| [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1 | Ac-225 | Preclinical | |
| [67Cu]Cu-pertuzumab-PEG6-DM1 | Cu-67 | Reported once |
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [177Lu]Lu-DOTA-A1K2 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-PEG-CPNs | Lu-177 | Preclinical | |
| Na131I | I-131 | — |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch